Evidence map›Paper›PMID 19114076›Full record

ArticleVaccine2009

Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.

Stéphanie G Trouche, Ayodeji Asuni, Sylvie Rouland, Thomas Wisniewski, Blas Frangione, Jean-Michel Verdier, Einar M Sigurdsson, Nadine Mestre-Francés

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Amyloid-beta immunotherapy for Alzheimer's disease.CNS & neurological disorders drug targets · 2010
    Review
  13. Article
  14. AD vaccines: conclusions and future directions.CNS & neurological disorders drug targets · 2009
    Review
  15. Review
  16. Article
  17. Vaccination as a therapeutic approach to Alzheimer's disease.The Mount Sinai journal of medicine, New York
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Stéphanie G TroucheUniversité Montpellier II, Montpellier F-34095, France; INSERM, U-710, Montpellier F-34095, France.
Ayodeji Asuni
Sylvie Rouland
Thomas Wisniewski
Blas Frangione
Jean-Michel Verdier
Einar M Sigurdsson
Nadine Mestre-Francés
New York University · USUniversité de Montpellier · FRÉcole Pratique des Hautes Études · FRInserm · FR

Funding

Detection and Clearance of AD LesionsR01AG020245 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WISNIEWSKI, THOMAS M · 2002 to 2016
$4.7M
AMYLOIDOSIS AND ALZHEIMERS DISEASER37AG005891 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI FRANGIONE, BLAS · 1997 to 2006
$3.3M
Immune Therapy for AD plaques and Tangles in Tg MiceR01AG020197 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SIGURDSSON, EINAR M · 2001 to 2013
$2.8M
AMYLOIDOSIS AND ALZHEIMERS DISEASER01AG005891 · NIA · NEW YORK UNIVERSITY · PI FRANGIONE, BLAS · 1985 to 1995
–
NIA NIH HHS AG05891NIA NIH HHS AG20197NIA NIH HHS AG20245NIA NIH HHS R01 AG020197NIA NIH HHS R01 AG020245NIA NIH HHS R37 AG005891
6 · The paper itself

Abstract

We have been developing Abeta derivative vaccines with the objective to improve the safety of Abeta targeting immunotherapy. Our Abeta homologs are designed to have less direct toxicity and to produce a modified immune response compared to Abeta. In extensive mouse studies, all our vaccines have improved cognition in transgenic mice while eliciting different immune responses and reducing brain amyloid burden to a variable degree. While we are continuing to characterize these vaccines in mice, in preparation for studies in old primates and for human trials we assessed their effect in young lemur primates (n=25) that with age develop Abeta plaques and tau aggregates as seen in Alzheimer's disease. In the primates, all the peptides administered with alum adjuvant elicited a moderate to robust anti-Abeta IgM response. Abeta1-42, K6Abeta1-30 and K6Abeta1-30[E(18)E(19)] resulted in a high anti-Abeta IgG response, whereas Abeta1-30[E(18)E(19)] produced a weaker more variable IgG titer. Notably, 22 weeks after the 3rd immunization, IgM and IgG levels in derivative-vaccinated primates were similar to preimmune values whereas Abeta1-42 treated primates maintained a moderate IgG titer. The increase in antibodies that recognized Abeta1-40 often correlated with increase in Abeta1-40 in plasma, which suggests that the antibodies were binding to Abeta in vivo. Interestingly, significant transient weight gain was observed (K6Abeta1-30-, Abeta1-30[E(18)E(19)]- and Abeta1-42-treated) or a trend in the same direction (K6Abeta1-30[E(18)E(19)]-treated, adjuvant controls) following the injections. Based on these findings, we have chosen K6Abeta1-30 for immunizations in old primates as the antibody response to this vaccine was less variable compared to other Abeta derivatives. Our present findings indicate that most of our Abeta derivatives elicit a substantial antibody response in primates, and importantly this effect is reversible which enhances the safety profile of our approach.

Indexed as

Antibody FormationAdjuvants, ImmunologicAlum CompoundsAlzheimer VaccinesAmyloid beta-PeptidesAnimalsBody WeightBrainCheirogaleidaeFemaleImmunoglobulin GImmunoglobulin MMalePeptide FragmentsPlasmaAdjuvants, ImmunologicAlum Compoundsaluminum sulfateAlzheimer Vaccinesamyloid beta (1-30)-amide, Glu(18,19)-Amyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Immunoglobulin GImmunoglobulin MLys-Lys-Lys-Lys-Lys-Lys-amyloid beta (1-30)-amideLys-Lys-Lys-Lys-Lys-Lys-amyloid beta (1-30)-amide, Glu(18,19)-Peptide Fragments

Identifiers

PMID19114076
PMCPMC2713060
OpenAlexW2078574808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.